Patrick Daly

DocwireNews

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive recommendation for avapritinib in adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms not controlled by therapies, according to avapritinib manufacturer, Blueprint Medicines Corporation.&ldquo;Indolent systemic mastocytosis is often characterized by severe symptoms, significant morbidities and high healthcare resource utilization, with a profound impact on patients and their families,&rdquo; stated Becker Hewes, MD, Chief Medical Officer of Blueprint Medicines, in a press release.Patients with systemic mastyocytosis (SM) are primarily treated with several symptom-directed medications, but many patients still experience symptoms. Avapritinib is a potent, selective inhibitor of KIT D816V, the primary driver of SM. If approved by the European Commission (EC), avapritinib will be the first treatment directed at the primary disease driver approved for the approximately 40,000 patients with ISM in Europe, according to the release.&ldquo;In Europe, patients with ISM currently have no approved therapies to target the underlying driver of disease, and the need to advance treatment beyond supportive care has never been more critical,&rdquo; said Frank Siebenhaar, MD, Head of University Outpatient Clinic at Charit&eacute; Institute of Allergology in Berlin.Currently, avapritinib is approved in the United States for adults with ISM and advanced SM. Avapritinib is also approved by the EMA for the treatment of advanced SM and PDGFRA D842V-mutated gastrointestinal stromal tumors.The positive recommendation from the CHMP was based on the pivotal PIONEER trial, which reported once-daily avapritinib was well-tolerated with favorable safety signals and predominantly mild adverse events. The EC will review the CHMP recommendation, and a final decision on the ISM indication is expected in Q1 2024.

Jordana Jampel

Successful HIV Viral Suppression With At-Home Administration

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Latest News

Avapritinib Receives Support for Indolent Systemic Mastocytosis Indication in Europe

Hematology

The Committee for Medicinal Products for Human Use of the European Medicines Agency supported the approval of avapritinib for indolent systemic mastocytosis in Europe.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe